A Phase 1 interventional study of KITE-585 and Cyclophosphamide in Relapsed/Refractory Multiple Myeloma, sponsored by Kite, A Gilead Company. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-19.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.
Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 130th largest by enrollment of the 167 interventional ones that give a count, is one of 15 that started in 2017, is one of 35 in phase 1, and was the 131st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Northside Hospital, Inc. · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 116 · Phase 3 16
First in 1988; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 167 interventional studies. Of the 119 that completed or were terminated, 68 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 171 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kite, A Gilead Company, one of the names counted as Gilead Sciences. Under that name alone:
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
14 studies in Multiple Myeloma by Gilead Sciences: 2 open now, 5 under way, 3 of them phase 3. Of 9 finished, 2 (22%) have results posted.
Among the 14 studies in Multiple Myeloma by Gilead Sciences, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 1, and was the 7th registered.
Gilead Sciences’s Multiple Myeloma studies by the year they started, since 2007.
8 of the studies testing cyclophosphamide in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909059Northside Hospital, Inc.CAR T-cell Therapy in Patients With Renal Dysfunction | 2026-12-31 |
| NCT04166565Stichting European Myeloma NetworkDaratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease | 2027-03 |
| NCT06623630Washington University School of MedicineLymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | 2027-06-30 |
| NCT05909826Dong-A University HospitalCarfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM | 2027-06-30 |
| NCT03710421City of Hope Medical CenterCS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | 2027-08-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 171 studies testing cyclophosphamide in Multiple Myeloma, from their registry updates:
Among Gilead Sciences’s 14 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limiting toxicities (DLTs). Participants will be given a 3 day course of conditioning chemotherapy followed by a single infusion of KITE-585.
Participants with relapsed/refractory multiple myeloma can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, ECG and echocardiogram of the heart, brain MRI, and blood draws. Eligible participants have white blood cells collected by leukapheresis. These cells are genetically modified to make the experimental treatment KITE-585. Participants receive conditioning chemotherapy prior to the KITE-585 infusion. After the KITE-585 infusion, participants will be followed for side effects and effect of KITE-585 on their myeloma. Study procedures may be performed while hospitalized and/or in the outpatient setting. Participants who received an infusion of KITE-585 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968
Key Inclusion Criteria:
Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^7 autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine
Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine
Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine
Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^9 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine
RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \[Grade 2 chronic kidney disease\]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 24 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a tolerable dose of 3 x 10\^7 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine
A single infusion of KITE-585 autologous anti-BCMA CAR T cells
Administered intravenously
Administered intravenously
Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
A DLT is a KITE-585-related event with onset in the first 28 days following infusion. DLTs are defined by events and duration of events, including: * Any duration: Grade (GR) 4 cytokine release syndrome (CRS), KITE-585-related GR 5 adverse events (AE) and GR 4 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 3 or better in ≤ 72 hours, hypogammaglobulinemia, tumor lysis syndrome, acute renal toxicity requiring dialysis for ≤ 7 days, intubation for airway protection for ≤ 7 days and AE resolves to ≤ GR 1 within 2 weeks and baseline within 4 weeks * ≥ 72 hours: GR 3 CRS and GR 3 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 2 or better in ≤ 14 days, hypogammaglobulinemia and tumor lysis syndrome * ≥ 30 days: GR 4 hematologic AE with the exceptions of cytopenias attributable to ongoing or recurrent multiple myeloma
Time frame: From KITE-585 infusion until 28 days after KITE-585 infusion
Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria
ORR: Percentage of participants who achieved a stringent CR (sCR), complete response (CR), partial response (PR), or very good PR (VGPR), as determined by IMWG Consensus Panel 1 Criteria. sCR: CR+normal free light chain (FLC) ratio, no clonal cells in BM by immunohistochemistry or immunofluorescence; CR: negative immunofixation (IFX) on serum and urine, no soft tissue plasmacytomas (STP), \<5% plasma cells in bone marrow (BM); PR: ≥50% decrease of serum M-protein + 24hr urinary M-protein decrease by ≥90% or \<200 mg/24hr. If unmeasurable serum and urine M-protein; and serum-free light assay; requires ≥ 50% decrease in the difference between involved and uninvolved FLC levels / ≥ 50% reduction in plasma cells (PC), provided baseline BM PC percentage was ≥ 30%, respectively. If present at baseline, ≥ 50% reduction in the size of STP is also required; VGPR: serum and urine M-protein detected by IFX but not electrophoresis, \>90% in serum M-protein+urine, M-protein level \<100 mg/24hr.
Time frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1
PFS: Interval from first study drug dose date to the earlier of first documentation of definitive progressive disease (PD) per IMWG Consensus Panel 1 Criteria or death from any cause. PD: an increase of 25% from the lowest response value in 1 of the following: Serum and urine M-protein (absolute increase ≥ 0.5 g/dL and ≥ 200 mg/24 hours, respectively); In participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase \> 10 mg/dL); In participants without measurable serum and urine M-protein and without measurable disease by FLC levels, bone marrow PC percentage (absolute percentage ≥ 10%). Definite development of new bone lesions or STP or definite increase in the size of existing bone lesions or STPs; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder. Analysis was done using Kaplan-Meier (KM) estimate.
Time frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Overall Survival (OS)
Overall survival is defined as the time from the first dose date of study drug to the date of death from any cause. Analysis was done using KM estimate. Participants who have not died by the analysis data cutoff date were censored at their last date known to be alive or cutoff date, whichever is earlier.
Time frame: From KITE-585 infusion to date of data cutoff (maximum: 17.6 months)
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame: Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first (maximum: 2.9 months)
Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities
Clinically significant laboratory abnormalities were defined as per investigator's discretion.
Time frame: Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first (maximum: 2.9 months)
Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1
DOR is defined for participants who experience an objective response and is defined as the time from the date of their first objective response (which is subsequently confirmed) to PD per IMWG Consensus Panel 1 Criteria or death from any cause, whichever is earlier. Objective response is defined in Outcome measure 2.
Time frame: From first response to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Time to Next Treatment (TTNT)
TTNT is defined as the length of time between the date of KITE-585 infusion to the date of initiation of the next therapy or death due to any cause, whichever is earlier.
Time frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Participants were enrolled at study sites in the United States.
| Milestone | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 4 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 4 | 3 | 4 | 3 |
| Withdrew: Death | 2 | 3 | 3 | 2 | 2 |
| Withdrew: Enrolled but never treated | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Informed consent withdraw | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal of consent from further follow-up | 1 | 0 | 0 | 0 | 0 |
A DLT is a KITE-585-related event with onset in the first 28 days following infusion. DLTs are defined by events and duration of events, including: * Any duration: Grade (GR) 4 cytokine release syndrome (CRS), KITE-585-related GR 5 adverse events (AE) and GR 4 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 3 or better in ≤ 72 hours, hypogammaglobulinemia, tumor lysis syndrome, acute renal toxicity requiring dialysis for ≤ 7 days, intubation for airway protection for ≤ 7 days and AE resolves to ≤ GR 1 within 2 weeks and baseline within 4 weeks * ≥ 72 hours: GR 3 CRS and GR 3 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 2 or better in ≤ 14 days, hypogammaglobulinemia and tumor lysis syndrome * ≥ 30 days: GR 4 hematologic AE with the exceptions of cytopenias attributable to ongoing or recurrent multiple myeloma
| percentage of participants | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 |
|---|---|---|---|---|
| Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 |
ORR: Percentage of participants who achieved a stringent CR (sCR), complete response (CR), partial response (PR), or very good PR (VGPR), as determined by IMWG Consensus Panel 1 Criteria. sCR: CR+normal free light chain (FLC) ratio, no clonal cells in BM by immunohistochemistry or immunofluorescence; CR: negative immunofixation (IFX) on serum and urine, no soft tissue plasmacytomas (STP), \<5% plasma cells in bone marrow (BM); PR: ≥50% decrease of serum M-protein + 24hr urinary M-protein decrease by ≥90% or \<200 mg/24hr. If unmeasurable serum and urine M-protein; and serum-free light assay; requires ≥ 50% decrease in the difference between involved and uninvolved FLC levels / ≥ 50% reduction in plasma cells (PC), provided baseline BM PC percentage was ≥ 30%, respectively. If present at baseline, ≥ 50% reduction in the size of STP is also required; VGPR: serum and urine M-protein detected by IFX but not electrophoresis, \>90% in serum M-protein+urine, M-protein level \<100 mg/24hr.
| percentage of participants | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria | 33.3 | 0 | 0 | 0 | 0 |
PFS: Interval from first study drug dose date to the earlier of first documentation of definitive progressive disease (PD) per IMWG Consensus Panel 1 Criteria or death from any cause. PD: an increase of 25% from the lowest response value in 1 of the following: Serum and urine M-protein (absolute increase ≥ 0.5 g/dL and ≥ 200 mg/24 hours, respectively); In participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase \> 10 mg/dL); In participants without measurable serum and urine M-protein and without measurable disease by FLC levels, bone marrow PC percentage (absolute percentage ≥ 10%). Definite development of new bone lesions or STP or definite increase in the size of existing bone lesions or STPs; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder. Analysis was done using Kaplan-Meier (KM) estimate.
| months | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1 | 1.1 (0.5 to 3.2) | 1.0 (0.9 to 1.0) | 0.8 (0.5 to 1.0) | 1.0 (0.9 to 1.0) | NA (2.0 to NA) |
Overall survival is defined as the time from the first dose date of study drug to the date of death from any cause. Analysis was done using KM estimate. Participants who have not died by the analysis data cutoff date were censored at their last date known to be alive or cutoff date, whichever is earlier.
| months | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Overall Survival (OS) | NA (11.1 to NA) | 5.1 (3.0 to NA) | 6.9 (3.2 to NA) | NA (5.5 to NA) | 12.2 (NA to NA) |
| percentage of participants | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
Clinically significant laboratory abnormalities were defined as per investigator's discretion.
| percentage of participants | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities | 0 | 0 | 0 | 0 | 0 |
DOR is defined for participants who experience an objective response and is defined as the time from the date of their first objective response (which is subsequently confirmed) to PD per IMWG Consensus Panel 1 Criteria or death from any cause, whichever is earlier. Objective response is defined in Outcome measure 2.
| months | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1 | NA | — | — | — | — |
TTNT is defined as the length of time between the date of KITE-585 infusion to the date of initiation of the next therapy or death due to any cause, whichever is earlier.
| months | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Time to Next Treatment (TTNT) | NA | NA | NA | NA | NA |
Collected over Adverse Events: Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first. (maximum: 2.9 months) All-Cause Mortality: Enrollment up to 57.6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: 3 x 10^7 KITE-585 | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation: 1 x 10^8 KITE-585 | 4/4 (100%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation: 3 x 10^8 KITE-585 | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation: 1 x 10^9 KITE-585 | 3/4 (75%) | 0/3 (0%) | 3/3 (100%) |
| Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 | 3/3 (100%) | 0/2 (0%) | 2/2 (100%) |
| Event | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/2 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/2 |
| Event | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/3 | 2/3 | 2/3 | 2/3 | 2/2 |
| NauseaGastrointestinal disorders | 0/3 | 1/3 | 3/3 | 1/3 | 1/2 |
| Neutrophil count decreasedInvestigations | 2/3 | 1/3 | 1/3 | 3/3 | 0/2 |
| HeadacheNervous system disorders | 0/3 | 1/3 | 1/3 | 1/3 | 2/2 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 2/3 | 2/3 | 0/3 | 1/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 2/3 | 0/3 | 1/2 |
| ConstipationGastrointestinal disorders | 0/3 | 1/3 | 2/3 | 0/3 | 0/2 |
| FatigueGeneral disorders | 0/3 | 1/3 | 1/3 | 2/3 | 1/2 |
| White blood cell count decreasedInvestigations | 2/3 | 2/3 | 1/3 | 1/3 | 0/2 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/3 | 1/3 | 2/3 | 2/3 | 0/2 |
The Full Analysis Set included all participants who were enrolled in the study.
| Age, Categorical(Participants) | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 2 | 4 | 2 | 14 |
| >=65 years | 0 | 1 | 1 | 0 | 1 | 3 |
| Age, Continuous(years) | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 | Total |
|---|---|---|---|---|---|---|
| Mean | 52.3 (50 to 56) | 59.8 (49 to 71) | 59.3 (49 to 67) | 54.3 (47 to 58) | 56.3 (47 to 65) | 56.5 (47 to 71) |
| Sex: Female, Male(Participants) | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 2 | 2 | 2 | 7 |
| Male | 3 | 3 | 1 | 2 | 1 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 3 | 4 | 3 | 4 | 2 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation: 3 x 10^7 KITE-585 | Dose Escalation: 1 x 10^8 KITE-585 | Dose Escalation: 3 x 10^8 KITE-585 | Dose Escalation: 1 x 10^9 KITE-585 | Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585 | Total |
|---|---|---|---|---|---|---|
| White | 3 | 3 | 1 | 3 | 3 | 13 |
| Black or African American | 0 | 1 | 1 | 1 | 0 | 3 |
| Other | 0 | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2018, 13 months.
Results were first posted in May 2020, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Fludarabine